Comparing the current results to its competitors, Absci reported Revenue decrease in the 2 quarter 2026 year on year by -46.37 %, despite the revenue increase by the most of its competitors of 1.44 %, recorded in the same quarter.
The company competes with pharmaceutical and biotechnology firms developing therapeutics targeting the same diseases as its internal programs. For ABS-201 in androgenetic alopecia (AGA), competitors include FDA-approved treatments such as oral minoxidil, oral finasteride, oral dutasteride, and topical minoxidil, as well as clinical-stage drug candidates like Hope Medicine’s HMI-115, Veradermics’ VDPHL01, Pelage Pharmaceuticals’ PP405, and Cosmo Pharmaceuticals’ Clascoterone. In endometriosis, competition includes emerging non-hormonal antibody-based therapies, including candidates from Hope Medicine. For inflammatory bowel disease (IBD), competitors include Merck’s MK-7240, Roche/Roivant’s RVT-3101, Sanofi/Teva’s TEV-48574 TL1A, Spyre’s SPY002, AbbVie’s ABBV-701, and Xencor’s XmAb942. In the field of AI-based drug design and discovery, competitors include Generate Biomedicines, Inc. and Xaira Therapeutics, Inc., among others. Named competitors across filings include AbbVie, Cosmo Pharmaceuticals, Generate Biomedicines, Inc., Hope Medicine, Merck, Pelage Pharmaceuticals, Roche/Roivant, Sanofi/Teva, Spyre, Veradermics, Xaira Therapeutics, Inc., and Xencor.
February 21, 2024
Absci, a leading synthetic biology company, has recently announced significant progress in the development of ABS-101, a promising anti-TL1A antibody. The company is utilizing its innovative Generative AI technology to design and optimize ABS-101, aiming to create a best-in-class therapeutic candidate. The initiation of IND-enabling studies marks a significant milestone in the development process, as Absci moves towards submitting the IND application in the first quarter of 2025. Phase 1 clinical trials for ABS-101 are expected to commence shortly after.Designing ABS-101 with Generative AIAbsci s cutting-edge Generative AI platform employs machine learning algorithms to harness vast biological datasets, acce...
January 8, 2024
In a recent announcement that has caused waves in the medical research community, Absci Corporation revealed it will present preclinical data for its much-anticipated ABS-101, a potential best-in-class Anti-TL1A Antibody Development Program, at the 42nd Annual J.P. Morgan Healthcare Conference. This burgeoning breakthrough in pharmaceuticals has surged new interest in developing potential best-in-class drugs.TL1A is a cytokine, a type of protein that plays a pivotal role in cellular signaling. TL1A is known to contribute to autoimmunity and inflammation by regulating T-cell responses. In layman s terms, a high level of TL1A activity can lead to harmful inflammation and autoimmune diseases. Hence, Anti-TL1A a...
In a fascinating twist to the narrative of biotech in 2023, Absci, an AI biologics company, has announced a dynamic strategic Research and Development Partnership with PrecisionLife, a forerunner in precision medicine. This partnership plans to combine the unique strengths of both companies strategically to develop an AI-enabled drug pipeline, set to revolutionize the future of novel drug treatments. While the global trend of revenue changes remains negative, the partnership between Absci and PrecisionLife promises to have an impact that could potentially defy this trend by counteracting a downturn. A significant revelation during the Q3, 2023, is Absci s reported year-on-year decrease of -68.59 % i...
Amgen Inc.s business model focuses on leveraging advanced biotechnology to create therapeutic products for various diseases, particularly in the fields of oncology, inflammation, and cardiovascular health. The company invests heavily in research and development to drive innovation, while also utilizing strategic partnerships and acquisitions to enhance its product pipeline. Additionally, Amgen emphasizes a strong global commercial presence to maximize the accessibility and impact of its therapeutics in the healthcare market.
Synlogic Inc's business model revolves around utilizing synthetic biology to develop innovative microbial engineering solutions. They focus on developing Synthetic Biotic medicines, which are living medicines designed to treat diseases by targeting specific metabolic or immuno-inflammatory pathways in the body.
Schrodinger Inc is a computational drug discovery company that utilizes physics-based solutions to accelerate the discovery and development of new drugs. Their business model involves providing software and services to pharmaceutical and biotechnology companies, enabling them to optimize and streamline their drug discovery processes. By leveraging their unique expertise in computational chemistry and molecular modeling, Schrodinger aims to empower their clients in the pursuit of efficient and effective drug development.
Recursion Pharmaceuticals Inc is a biotech company that utilizes its artificial intelligence (AI) platform to identify and develop potential drug candidates. They employ a unique approach by combining AI technology with experimental biology and automation to accelerate drug discovery. Recursion applies its platform to identify new treatments for rare diseases and have established partnerships with various organizations in the pharmaceutical industry.
Relay Therapeutics Inc is a biotechnology company focused on developing targeted therapies for diseases by leveraging insights from protein motion. Their business model involves utilizing computational simulations and algorithms to discover and design small molecule therapies that can effectively target specific proteins involved in various diseases.
Sources:
Absci Corp’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Absci Corp versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
